Prevalence and characteristics of adults with preserved ratio impaired spirometry (PRISm): Data from the BOLD Australia study
<b>Background:</b> Individuals with Preserved Ratio Impaired Spirometry (PRISm), defined as FEV<sub>1</sub>/FVC ≥0.7 and FEV1 <80% predicted, are at higher risk of developing COPD. However, data for Australian adults are limited. We aimed to describe prevalence of PRISm and its relationship with clinical characteristics in Australia. <b>Method:</b> Data from the Burden of Lung Disease (BOLD) Australia study of randomly selected adults aged ≥40 years from six sites was classified into airflow limitation, PRISm, or normal spirometry groups. Demographic, clinical characteristics, and lung function were compared between groups. <b>Results:</b> Of the study sample (<i>n</i> = 3518), 387 (11%) had PRISm, 549 (15.6%) had airflow limitation, and 2582 (73.4%) had normal spirometry. PRISm was more common in Indigenous Australian adults. Adults with PRISm had more frequent respiratory symptoms, more comorbidities, greater health burden and poorer quality of life than those with normal spirometry. Pre- and post-bronchodilator FEV<sub>1</sub> and FVC were lower in adults with PRISm than those with airflow limitation. Adults with PRISm were less likely to use respiratory medicine than those with airflow limitation (OR = 0.56, 95% CI 0.38-0.81). <b>Conclusions:</b> PRISm was present in 11% of adults in this study and they had similar respiratory symptoms and health burden as adults with airflow limitation.
Authors
- Richard Wood‐Baker
- Helen Kathryn Reddel (ORCID: https://orcid.org/0000-0002-6695-6350)
- R Ampon (ORCID: https://orcid.org/0000-0001-5397-4691)
- DP Johns (ORCID: https://orcid.org/0000-0002-1575-6850)
- Guy B. Marks (ORCID: https://orcid.org/0000-0002-8976-8053)
- Michael J. Abramson (ORCID: https://orcid.org/0000-0002-9954-0538)
- Yijun Zhou (ORCID: https://orcid.org/0000-0003-2352-0407)
- Anthony James (ORCID: https://orcid.org/0000-0002-2742-8328)
- Graeme Maguire (ORCID: https://orcid.org/0000-0003-3817-4885)
- Brett G. Toelle (ORCID: https://orcid.org/0000-0002-7375-0019)
Institutions
- The University of Sydney (AU)
- The University of Melbourne (AU)
- Curtin University (AU)
- Woolcock Institute of Medical Research (AU)
- Sir Charles Gairdner Hospital (AU)
- UNSW Sydney (AU)
- Sydney Local Health District (AU)
- South Western Sydney Local Health District (AU)
- Monash University (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Chronic Respiratory Disease
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1177/14799731241312687
- Citations
- 6
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 9.11
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Pfizer Australia
- GlaxoSmithKline Australia
- University of Tasmania
- Charles Sturt University
- Monash University
- Medical Research Council
- National Health and Medical Research Council